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Abstract
Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the most common dose-limiting 
adverse effects of several chemotherapeutic agents, such as platinum derivatives (oxaliplatin and cisplatin), taxanes, vinca 
alkaloids and bortezomib. CIPN affects more than 60% of patients receiving anticancer therapy and although it is a nonfatal 
condition, it significantly worsens patients’ quality of life. The number of analgesic drugs used to relieve pain symptoms 
in CIPN is very limited and their efficacy in CIPN is significantly lower than that observed in other neuropathic pain types. 
Importantly, there are currently no recommended options for effective prevention of CIPN, and strong evidence for the utility 
and clinical efficacy of some previously tested preventive therapies is still limited.
Methods The present article is the second one in the two-part series of review articles focused on CIPN. It summarizes the 
most recent advances in the field of studies on CIPN caused by oxaliplatin, the third-generation platinum-based antitumor 
drug used to treat colorectal cancer. Pharmacological properties of oxaliplatin, genetic, molecular and clinical features of 
oxaliplatin-induced neuropathy are discussed.
Results Available therapies, as well as results from clinical trials assessing drug candidates for the prevention of oxaliplatin-
induced neuropathy are summarized.
Conclusion Emerging novel chemical structures—potential future preventative pharmacotherapies for CIPN caused by 
oxaliplatin are reported.
Graphical abstract
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Oxaliplatin as a neurotoxic drug
Oxaliplatin (trans-l-diaminocyclohexane oxalate platinum 
(II), Fig. 1), a third-generation platinum-based chemother-
apeutic agent [1], has been placed on the World Health 
Organization’s List of Essential Medicines [2]. Similar to 
other platinum-based compounds (e.g., cisplatin, carbopl-
atin), oxaliplatin interferes with tumor cell proliferation by 
forming deoxyribonucleic acid (DNA)-platinum adducts, 
which leads to cancer cell destruction [1].
Clinically, oxaliplatin is used in combination with 
folinic acid and 5-fluorouracil as a part of the FOLFOX 
regimen or with folinic acid, 5-fluorouracil and irinotecan 
Fig. 1  Chemical structure of oxaliplatin, its biotransformation path-
ways and a potential mechanism underlying the development of 
oxaliplatin-induced neuropathy: oxaliplatin (I) is rapidly hydro-
lyzed  in vivo  to bioactive derivatives through the displacement of 
the oxalate group by  H2O and  Cl− ions to produce oxalate (II) as well 
as reactive monochloro-diaminocyclohexane (DACH) (III), dichloro-
DACH (IV) and diaquo-DACH platinum (V) metabolites. Oxalate, 




(FOLFOXIRI) regimen as the first-line and as adjuvant 
colorectal cancer therapy [3].
Recent preclinical studies have shown that transporter-
mediated uptake of oxaliplatin (and paclitaxel [4, 5]) into 
dorsal root ganglia neurons might trigger pathophysiologi-
cal changes in sensory neurons, thus resulting in chemo-
therapy-induced peripheral neuropathy (CIPN) develop-
ment [4].
The organic cation/carnitine transporters OCTN1 and 
OCTN2 belong to the organic cation transporter family. 
These proteins are responsible for transporting oxaliplatin 
and are regarded as key transporters maintaining the intra-
cellular concentration of platinum derivatives via active 
uptake and efflux processes. OCTN1 and OCTN2 are also 
functionally expressed within dorsal root ganglia neurons, 
and OCTN1 is thought to be the main contributor to the neu-
ronal accumulation of oxaliplatin and a mediator of its neu-
rotoxicity [4, 6–8]. In addition, CTR1 (copper transporter 1), 
CTR2 (copper transporter 2), ATP7A (copper-transporting 
p-type adenosine triphosphatase 1) and ATP7B (copper-
transporting p-type adenosine triphosphatase 2) are copper 
transporters that not only maintain homeostasis and copper 
metabolism but also are involved in cisplatin, carboplatin 
and oxaliplatin transport. A high CTR1 level is regarded as 
a predictor of prolonged survival and enhanced response to 
chemotherapy in cancer patients [9].
A unique feature of oxaliplatin is that it is rapidly and 
non-enzymatically transformed into several metabolites, 
including oxalate, monochloro-, dichloro- and diaquo-
diaminocyclohexane (DACH) platinum metabolites (Fig. 1). 
This occurs via the replacement of the oxalate moiety with 
chloride ions and water in the blood plasma. The formation 
of these metabolites distinguishes oxaliplatin from cisplatin. 
Of note, oxalate is thought to be responsible for the cold-
induced hypersensitivity observed in oxaliplatin-treated, but 
not cisplatin-treated, patients [10, 11], although additional 
mechanisms, including the binding of platinum complexes 
to cellular proteins, have also been suggested [12].
Oxalate is a well-known calcium chelator [13], and 
oxalate-induced pain is regarded as a consequence of the 
chelation of extracellular calcium ions (i.e., the removal 
of extracellular calcium ions), which in turn leads to the 
increase in sodium conductance, neuronal depolarization 
and hyperexcitability (Fig. 1) [14, 15].
An increase in extracellular calcium concentration 
increases the probability of voltage-gated sodium  (Nav) 
channel closure and results in decreased excitability of 
peripheral neurons. Hence, the administration of calcium 
and magnesium ions before oxaliplatin infusion was eval-
uated in several clinical trials as a strategy to prevent the 
development of oxaliplatin-induced peripheral neuropathy, 
although clinical benefits of this approach were not con-
firmed [16, 17].
Genetic polymorphisms associated 
with oxaliplatin‑induced neuropathy
Data from mouse studies show that similarly to humans, 
various mouse strains exposed to oxaliplatin develop 
chemotherapy-induced peripheral neuropathy (CIPN). Sig-
nificant and strain-dependent differences were observed 
in the severity and behavioral features of CIPN. This sup-
ports the hypothesis that, for oxaliplatin, a genetic com-
ponent might be relevant for CIPN development, both in 
rodent models and in clinical settings. Importantly, these 
different neurotoxic phenotypes seem to be crucial in the 
choice of an appropriate mouse strain for CIPN studies 
[18].
Genetic risk factors associated with the development of 
CIPN have been studied recently [19]. As such, they can 
influence the absorption, distribution, metabolism or excre-
tion of chemotherapeutic agents that are responsible for 
CIPN formation. It was suggested that polymorphisms of 
glutathione transferases, cytochrome P450 enzymes and 
ATP binding cassette transporters may be involved in the 
development of platinum-induced CIPN [5, 20–22]. The 
Ile105Val polymorphism of the GSTP1 gene, encoding 
glutathione S-transferase P1, has been associated with a 
decreased risk of oxaliplatin-related CIPN. This mutation 
increases the activity of glutathione S-transferase P1, result-
ing in the increased conjugation of hydrophobic and elec-
trophilic compounds with glutathione, thus reducing their 
toxicity [23].
In addition, genetic or pharmacological knockout of 
OCT2 prevented the development of cold and mechanical 
hypersensitivity following oxaliplatin therapy, suggesting 
that the OCT2 transporter plays a key role in oxaliplatin-
induced cytotoxicity [24].
A polymorphism in the ABCC2 (ATP binding cassette 
subfamily C member 2) gene coding for the multidrug 
resistance protein 2 (MRP2) that leads to higher oxaliplatin 
concentrations in neurons was associated with oxaliplatin-
induced neurotoxicity [25]. Genetic variants of AGXT (ala-
nine glyoxylate aminotransferase) gene coding for alanine 
glyoxylate aminotransferase (i.e., an enzyme involved in 
oxalate metabolism) have been correlated with the severity 
of CIPN in patients on oxaliplatin therapy [26]. The develop-
ment of acute oxaliplatin-induced peripheral neuropathy was 
altered in patients with single-nucleotide polymorphisms in 
SCNA genes encoding selected  Nav channels. A polymor-
phism (rs2302237) in the SCN4A gene, which encodes the 
 Nav1.4 channel and a polymorphism (rs1263292) in the 
SCN10A coding for  Nav1.8 channel have been associated 
with an increased incidence of acute oxaliplatin-induced 
CIPN [27], while a polymorphism (rs6746030) in the 
SCN9A gene, which encodes the  Nav1.7 channel, protected 
against severe oxaliplatin-induced CIPN [28].
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Clinical features of oxaliplatin‑induced CIPN
In contrast to cisplatin, oxaliplatin is not nephrotoxic or 
ototoxic, but its use is still associated with various adverse 
effects, including myelotoxicity and CIPN. Neurotoxicity 
of oxaliplatin appears in two distinct forms, i.e., acute and 
chronic [29]. The acute, transient neuropathy develops in 
almost 90% of patients within hours of infusion and lasts a 
few days (usually 7 days), recurring with subsequent infu-
sions. Acute neuropathy results from a transient impairment 
of ion channels and nerve hyperexcitability due to  Nav chan-
nel activation [30, 31] and is characterized by dysesthesia 
and paresthesia of the hands and feet. These symptoms are 
often exacerbated by cold. Motor symptoms (e.g., tetanic 
spasms, fasciculations, prolonged muscular contractions) 
can also be present in patients on oxaliplatin therapy. The 
acute form of oxaliplatin-induced CIPN tends to weaken 
between treatment cycles, but prolonged exposure to this 
drug often leads to the development of a severe chronic form 
of CIPN.
The incidence of chronic peripheral neuropathy following 
oxaliplatin treatment has been estimated as approximately 
70% [32, 33]. Clinically, the symptoms of chronic oxalipl-
atin-induced neuropathy closely resemble those of the acute 
form and include paresthesia, hypoesthesia and dysesthesia 
of the hands and feet. Additionally, changed proprioception 
negatively affecting normal daily activities that require fine 
motor coordination might also occur [34, 35]. The main 
mechanism responsible for the observed permanent distal 
sensory loss is associated with the death of sensory neurons 
(i.e., nerve cell necrosis) due to the binding of oxaliplatin to 
mitochondrial DNA [36].
It has been estimated that the development of CIPN due 
to oxaliplatin administration is likely to occur at cumula-
tive doses exceeding 780–850 mg/m2 [29, 35, 37, 38]. The 
symptoms that occur may worsen or appear weeks to sev-
eral months after the completion of therapy (‘coasting’ phe-
nomenon), and the estimated prevalence of these persistent 
symptoms is approximately 60% of patients; these patients 
report long-lasting neuropathic symptoms that negatively 
interfere with their daily functions and significantly impair 
their quality of life [29, 34]. Importantly, overall recovery 
from CIPN symptoms is usually incomplete and might last 
up to five years following oxaliplatin chemotherapy cessa-
tion [39].
Symptoms of acute and chronic neuropathy were evalu-
ated in patients receiving an adjuvant FOLFOX regimen in 
a phase III clinical trial (ClinicalTrials.gov: NCT00316914). 
Acute neuropathy was assessed for 6 days with each cycle 
of FOLFOX. Chronic neuropathy was evaluated until 
18 months after chemotherapy cessation. Acute neuropa-
thy symptoms included sensitivity to touching cold items, 
sensitivity to swallowing cold items, throat discomfort, 
and muscle cramps. Acute symptoms peaked at day 3 and 
improved, but they tended not to resolve completely between 
treatments. For chronic neurotoxicity, tingling was the most 
severe symptom, followed by numbness and then pain. 
Patients with more severe acute neuropathy during the first 
cycle of therapy experienced more severe chronic sensory 
neurotoxicity [40].
Available preventative therapies for CIPN 
caused by oxaliplatin
Considering the severity of CIPN and its irreversibility in 
a large proportion of patients, for many years efforts have 
been being made to alleviate this pharmacoresistant clinical 
condition. Therefore, the National Cancer Institute’s Symp-
tom Management and Health-Related Quality of Life Steer-
ing Committee has announced that CIPN is a priority area 
of translational research in cancer care [4]. Even the latest 
literature data clearly indicate that although numerous pre-
ventative therapies were tested for their potential utility for 
CIPN alleviation, this clinical entity currently is still not pre-
ventable [41–43], and many strategies tested were found to 
be ineffective (Table 1). Therefore, based on meta-analyses 
of clinical trials, at present, no drug can be proposed as a 
gold standard to either prevent CIPN or treat its symptoms, 
Table 1  A summary of ASCO recommendations for preventative therapies for CIPN [41, 44–50]
Strength of recommendation Drug
Recommendation strong against Acetyl-l-carnitine, diethyldithiocarbamate (DDTC), nimodipine, BIA 10-2474
Recommendation moderate against Amifostine, amitriptyline, calcium and magnesium infusions, glutathione, 
Org-2766 (ACTH analog), pregabalin, retinoic acid, emfilermin (rhuLIF), 
vitamin E
Inconclusive data: balance of benefits and harms Acetylcysteine, alpha-lipoic acid, carbamazepine, oxcarbazepine, glutamate, 
glutamine, goshajinkigan, neurotropin, omega-3 fatty acids, venlafaxine, 
vitamin B complex
Recommendation moderate for Duloxetine
Recommendation strong for None
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and chemotherapeutic drug dose modification remains the 
only preventative strategy [41].
Several clinical trials aimed to examine potentially neu-
roprotective therapies to prevent CIPN. Based on the data 
obtained, only duloxetine is moderately recommended by 
the American Society of Clinical Oncology (ASCO) for the 
prevention of oxaliplatin-induced CIPN (Table 1) [44, 45]. 
These guidelines undoubtedly show that there are no clear 
algorithms for CIPN prevention because high-quality and 
strong evidence for the preventative action of agents tested 
is not available.
It should also be noted that many other drugs have been 
assessed, but their utility for the prevention of oxaliplatin-
induced CIPN is still controversial (Table 1). For example, 
venlafaxine and neurotropin are also not recommended for 
routine use because of insufficient information on their clini-
cal efficacy. A pilot randomized, placebo-controlled, double-
blinded phase III trial (ClinicalTrials.gov: NCT01611155) 
tested the use of venlafaxine to prevent oxaliplatin neurotox-
icity in 50 patients with stage II-IV colon cancer. The results 
of this study supported neither the use of venlafaxine for 
the prevention of oxaliplatin-induced neuropathy in clinical 
practice nor the initiation of a further phase III trial for an 
investigation of venlafaxine in this setting [51].
Pregabalin was also assessed in a phase III, randomized, 
double-blind, placebo-controlled clinical trial for its effi-
cacy and safety in the prevention and reduction of oxali-
platin-induced painful neuropathy (PreOx; ClinicalTrials.
gov: NCT01450163). Patients received either pregabalin or 
placebo for 3 days before and 3 days after each oxaliplatin 
infusion and were followed for up to 6 months. The preemp-
tive use of pregabalin during oxaliplatin infusions was safe, 
but it did not decrease the incidence of CIPN (Table 1) [41, 
52].
Carbamazepine, oxcarbazepine, glutamate and glutamine, 
goshajinkigan, oral alpha-lipoic acid, omega-3 fatty acids 
and oral vitamin B complex are not recommended as CIPN-
preventing drugs because of their inconclusive data, low 
level of evidence and low strength of available evidence 
(Table 1) [41, 45, 48, 50, 53–57].
Other trials on potentially promising drug candidates for 
CIPN prevention, such as a fatty acid amide hydrolase inhib-
itor (BIA 10-2474, Table 1), were prematurely terminated 
due to serious adverse events noted in participants (death, 
severe neurological complications) [44].
Duloxetine
Evidence from preclinical [58, 59] and clinical studies [4] 
suggests that duloxetine, an antidepressant drug acting as 
a serotonin-noradrenaline reuptake inhibitor (SNRI), may 
be effective in the prevention of CIPN without reducing the 
antitumor activity of oxaliplatin [49]. As shown in Table 1, 
ASCO recommends duloxetine as the only potential treat-
ment for CIPN, but importantly, this guidance still lacks the 
support of sufficient evidence. Moreover, since in clinical 
trials duloxetine was not fully effective and it did not work in 
every patient enrolled, the identification of strong predictors 
for duloxetine response is a priority area of research. Results 
from a phase III double-blind trial of oral duloxetine for 
the treatment of pain associated with chemotherapy-induced 
peripheral neuropathy (ClinicalTrials.gov: NCT00489411) 
revealed that oxaliplatin-treated patients with high emotional 
functioning are more likely to experience pain reduction 
resulting from duloxetine administration [14].
Since patients with oxaliplatin-induced painful CIPN 
are more likely to benefit from the use of duloxetine than 
those with paclitaxel-induced CIPN, this also suggests that 
duloxetine’s mechanism of action may be closely associated 
with very specific molecular mechanisms underlying oxali-
platin-induced neurotoxicity [14, 60]. This possibility has 
not been fully explained, so far, and it seems to be even more 
exciting in terms of a distinct clinical efficacy of duloxetine 
and venlafaxine, both being representatives of SNRI anti-
depressants. Their efficacy was directly compared in cancer 
patients who were suffering from CIPN. The administration 
of duloxetine was more effective than that of venlafaxine in 
decreasing the symptoms of peripheral neuropathy due to 
chemotherapy. Duloxetine had a better effect on reducing 
the grade of motor neuropathy and neuropathic pain severity 
[61]. A potential explanation for this observed diversity in 
effectiveness is the difference in the pharmacological profile 
of both drugs. Compared to other SNRIs, venlafaxine has 
a high affinity for the serotonin transporter (SERT) but a 
relatively lower affinity for the norepinephrine transporter 
(NET), so at lower doses, it may act as a selective serotonin 
reuptake inhibitor (SSRI) and may not have the same activity 
against painful neuropathy as duloxetine [51].
Drug candidates for the prevention of CIPN 
caused by oxaliplatin
Since CIPN is not preventable using currently available 
drugs, there is a strong medical demand to search for novel 
therapeutic options for this clinical entity. Our understand-
ing of the complexity of neurobiological mechanisms 
implicated in CIPN symptomatology (altered ion channel 
expression, neuronal hyperexcitability, mitochondrial dys-
function, impaired immune cell signaling and axon degen-
eration) has constituted a basis for extended research on 
pharmacological prevention of CIPN. In this context, not 
only novel chemical compounds but also repurposed drugs 
are being investigated at preclinical and clinical stages of 
research. Considering the risk factors and causes of CIPN 
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development, several potential approaches have been pro-
posed (Fig. 2) [44].
An ‘ideal’ CIPN-preventing drug should have the fol-
lowing features: (i) it should act as a multitarget agent, as 
this might increase its protective efficacy; (ii) it should not 
diminish the antitumor efficacy of the chemotherapeutic 
used; and (iii) it should be introduced into therapy relying 
on an individual patient’s reported outcomes to increase its 
efficacy in preventing the symptoms and causes of CIPN. 
Several experimental therapies for CIPN prevention have 
reached the clinical stage of testing. These emerging drug 
candidates are shown in Table 2 and Fig. 2.
Targeting chemotherapeutic drug uptake 
transporters: tyrosine kinase inhibitors
In vitro and in vivo studies have shown that two tyrosine 
kinase inhibitors, nilotinib (an OATP1B2 inhibitor) and 
dasatinib (an OCTN2 inhibitor), might offer a potential 
neuroprotective strategy for CIPN caused by paclitaxel 
and oxaliplatin (Fig. 2) without negatively impacting their 
Fig. 2  Potential preventative 
therapies for CIPN caused by 
oxaliplatin: clinically tested 
drug candidates, repurposed 
drugs and preclinically 
tested lead compounds. APE 
apyrimidinic endonuclease/
redox effector factor, GAT-1 
γ-aminobutyric acid (GABA) 
transporter isoform 1, Glu 
glutamate, GLT-1 glutamate 




reactive oxygen species, 
TLR4 toll-like receptor 4, Nav 
voltage-gated sodium chan-
nels, Cav voltage-gated calcium 
channels, TREK-1 two-pore-
domain background potassium 
channel, TRPA1 Transient 
Receptor Potential Ankyrin-
repeat 1 channel, IL interleukin, 
TNFα tumor necrosis factor α, 
SARM-1 sterile alpha and TIR 
motif-containing protein 1, ATP 
adenosine triphosphate, Bclw 
Bcl2 family member, NOP noci-
ceptin opioid peptide receptor, 
S1P1 sphingosine-1-phosphate 
receptor type 1, OATP1B2 
solute carrier organic anion-
transporting polypeptide B2, 
OCTN2  Na+-dependent organic 
cation/carnitine transporter, 
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systemic clearance or antitumor efficacy. As repurposed 
drugs, nilotinib and dasatinib are currently being tested in 
an ongoing phase Ib trial and in double-blinded, placebo-
controlled, randomized phase II studies (Table 2) [4].
Targeting mitochondrial dysfunction and oxidative 
stress
Oxidative stress caused by chemotherapy is a significant 
contributor to mitochondrial damage, and reactive oxygen 
species (ROS) neutralization is a potential preventative strat-
egy for CIPN. Manganese superoxide dismutase (MnSOD) 
catalyzes the dismutation of superoxide and forms hydrogen 
peroxide and molecular oxygen. Hence, this enzyme limits 
the reaction of superoxide with nitric oxide, thus prevent-
ing the formation of the reactive and highly toxic nitrogen 
species peroxynitrite, which is able to nitrate the tyrosine 
residue of tissue proteins [64]. Recently, targeting MnSOD 
has emerged as a very promising strategy to prevent CIPN 
caused by oxaliplatin [83–86].
Calmangafodipir
Calmangafodipir (Ca4Mn(DPDP)5, PledOxVR), a derivative 
of mangafodipir, a magnetic resonance imaging contrast and 
a cytoprotectant agent [87, 88], is a mitochondrial MnSOD 
mimetic that reduces ROS tissue levels (Fig. 2). Although 
preclinical and clinical data have confirmed that such com-
pounds have significant preventative neuroprotective activity 
in oxaliplatin-induced CIPN [83–86], it is hypothesized that 
neuroprotection from calmangafodipir may also be possible 
with other chemotherapeutics [4, 64].
In a placebo-controlled, double-blinded, randomized, 
phase II study in patients with metastatic colorectal can-
cer (Table 2), calmangafodipir reduced cold allodynia and 
other sensory symptoms during and after treatment with 
oxaliplatin. The neuroprotective effects seen were clinically 
meaningful, as a delay in both the onset and the reduction 
of the intensity of CIPN symptoms were noted both in the 
acute and in the chronic phase of neuropathy. In this trial, 
progression-free and overall survival outcomes were not 
negatively influenced by calmangafodipir [64].
Two international trials, POLAR A and POLAR M are 
currently evaluating the efficacy of calmangafodipir for the 
prevention of oxaliplatin-induced neuropathy in colorectal 
cancer patients. Results are expected in the years 2020/2021 
(POLAR A) or 2021–2023 (POLAR M) [4, 62].
Apart from CIPN, calmangafodipir has also shown 
efficacy in severe paracetamol overdose and, based on 
results from a clinical trial (POP Trial, Clinicaltrials.gov: 
NCT03177395), might be regarded as an adjuvant or alterna-
tive to the N-acetylcysteine antidote for paracetamol over-






























































































































































































































































































































































































































































was gastrointestinal toxicity (nausea, vomiting, diarrhea, 
dyspepsia) [90–92].
Targeting apurinic/apyrimidinic endonuclease 
function
Another mechanism of nerve injury that underlies CIPN 
formation is associated with impaired DNA repair within 
the sensory nervous system. The pathway for base exci-
sion repair is the primary means for the repair of oxidative 
DNA damage. In this pathway, the enzyme apyrimidinic 
endonuclease/redox effector factor (APE1) is an important 
molecule for the removal of the damaged bases. Decreased 
APE1 levels in sensory neurons increase neurotoxicity 
and targeting APE1 by the small molecules APX3330 and 
APX2009 (Fig. 2) provided neuroprotection against cispl-
atin- and oxaliplatin-induced neurotoxicity. APX2009 also 
demonstrated a strong tumor cell-killing effect. These data 
suggest that such compounds might be effective in prevent-
ing or reversing platinum-induced CIPN without reducing 
the anticancer activity of platinum-based chemotherapeu-
tics [93]. Currently, APX3330 is entering clinical trials as 
an antineoplastic agent as well for the prevention of CIPN 
(Table 2) [94].
Targeting the inhibition of neuronal apoptosis 
and astrocyte activation
Impaired sphingolipid metabolism is also considered a 
mechanism contributing to CIPN development. Certain 
chemotherapeutics, including paclitaxel [66], oxalipl-
atin [95] and bortezomib [96], induce the development of 
CIPN by dysregulating sphingolipid metabolism, leading 
to increased formation of sphingosine-1-phosphate (S1P), 
which binds and stimulates sphingosine-1-phosphate 
receptor 1 (S1PR1). In rodent models of CIPN, the cera-
mide metabolic pathway was activated in the spinal cord, 
and blocking the formation of S1P with sphingosine kinase 
inhibitors reversed CIPN symptoms, mainly allodynia and 
hyperalgesia [66].
Fingolimod (FTY720; Table 2, Fig. 2) acts as a non-
selective agonist of  sphingosine-1-phosphate receptors 
(S1P1R, S1P3R, S1P4R, and S1P5R but not S1P2R). Fin-
golimod phosphate activates S1P1Rs with high potency 
(KD = 0.3  nM) and with higher efficacy than S1P. The 
overactivation of S1P1R caused by fingolimod results in 
rapid receptor desensitization and internalization. Thus, 
fingolimod behaves as a selective functional antagonist 
of the S1P1R subtype through the induction of receptor 
downregulation. The downstream effect of S1P1R block-
ade is the inhibition of the NF-κB pathway [97]. At present, 
fingolimod is commercially available as a marketed drug 
for multiple sclerosis, but its daily injections also inhibited 
the development of mechanical allodynia and hyperalgesia 
induced by paclitaxel, oxaliplatin, and bortezomib. Simi-
lar effects were also noted with other S1P1R antagonists. 
Moreover, a prolonged treatment with fingolimod or other 
S1P1R functional antagonists did not induce tolerance to 
their analgesic effects. S1P1R antagonists inhibited the 
development of CIPN, but they were also able to induce a 
sustained reversal of paclitaxel-induced neuropathic pain. 
Apart from fingolimod, novel S1PR modulators are being 
developed, including ponesimod [66], siponimod [98], and 
CYM5442, as well as selective S1P1R antagonists, includ-
ing W146, NIBR-14/15, and TASP0251078, as novel drug 
candidates for the treatment of various diseases, including 
multiple sclerosis, rheumatoid arthritis, colitis and cancer 
[99–101]. Importantly, the S1PR1 antagonists developed 
to date are not expected to reduce the anticancer activity 
of chemotherapeutic agents, and they may act synergisti-
cally [97, 102], making fingolimod and its analogs attractive 
agents for CIPN prevention [101]. Transient cardiovascular 
adverse effects of fingolimod result from a transient activa-
tion of S1P1R—a phenomenon that precedes its functional 
antagonism. These cardiovascular adverse effects include 
first-dose bradycardia, atrioventricular conduction block and 
hypotension, and they must be cautiously considered when 
utilizing this drug for CIPN prevention and treatment [4].
Monosialotetrahexosylganglioside (GM1) is a gly-
cosphingolipid located in the outer layer of the plasma mem-
brane (Fig. 2). It is critical for nerve development, differen-
tiation and repair after the injury as it has neuroprotective, 
neurotrophic-factor-like activity by activating the Trk neuro-
trophin receptors [103, 104]. GM1 can also prevent seizures 
and oxidative stress [105]. Initially, GM1 was approved for 
the treatment of vasculogenic or traumatic central nervous 
impairments and Parkinson’s disease, and now its potential 
procognitive activity is also suggested [103].
In a clinical trial conducted in colon cancer patients on 
FOLFOX therapy (Table 2), GM1 attenuated symptoms of 
acute neuropathy (cold sensitivity, throat discomfort, muscle 
cramps), but its use to prevent the neurotoxicity of oxalipl-
atin is currently not recommended, and additional placebo-
controlled studies are needed to better assess the utility of 
this agent in this clinical condition [4, 67].
Sodium channel inhibition
Nav channels are an important target for analgesic drugs used 
in neuropathic pain conditions. Most of the available  Nav 
inhibitors nonselectively block  Nav channels within the sen-
sory nervous system. From these drugs, lidocaine (Table 2, 
Fig. 2), a local anesthetic agent, will be assessed in a pilot 
study to determine the tolerability and the efficacy of its 
intravenous administration for the prevention of oxaliplatin-
induced cold hypersensitivity and spontaneous pain in the 
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setting of mFOLFOX6 chemotherapy for advanced colorec-
tal cancer [72].
Among  Nav channels,  Nav1.7 plays an important role 
in multiple neuropathic pain states. It was shown that the 
expression and function of  Nav1.7 are increased in preclini-
cal models of CIPN [106, 107]. Data from a randomized, 
double-blind, placebo-controlled pilot study investigating 
the efficacy of a  Nav1.7 antagonist, XEN402, indicate that 
it is effective in patients with inherited erythromelalgia, but 
so far, this compound has not been assessed in CIPN [4].
Sigma‑1 receptor antagonism
Selective sigma-1 receptor antagonists (e.g., MR309) attenu-
ated oxaliplatin-induced CIPN [76], and it was suggested 
that sigma-1 receptors might constitute a novel drug target 
for CIPN-preventing drugs [77]. Currently, MR309 (400 mg/
day, 5 days per cycle) has completed a phase II randomized, 
double-blind and placebo-controlled clinical trial in patients 
with colorectal cancer receiving FOLFOX, showing efficacy 
and a good safety profile in patients on oxaliplatin therapy 
[76]. Compared to placebo, MR309 significantly reduced 
the cold pain threshold temperature and lowered the pro-
portion of patients with severe chronic neuropathy. MR309 
increased the total amount of oxaliplatin delivered and it 
attenuated motor hyperexcitability symptoms in patients 
with colorectal cancer treated with oxaliplatin. A potential 
neuroprotective role of MR309 for acute and chronic CIPN 
induced by oxaliplatin was demonstrated. Taken together, it 
has been suggested that MR309 might be a first-in-class drug 
with a novel mechanism of action to improve some signs and 
symptoms of acute CIPN (e.g., cold pain and motor symp-
toms) caused by oxaliplatin. However, it has to be noted that 
further studies should be focused on testing different dose 
regimens of MR309 administration and continuous dosing 
during the full chemotherapy period [76].
Angiotensin II type 2 receptor antagonism
EMA401 (olodanrigan) is an angiotensin II type 2  (AT2) 
receptor antagonist. In clinical trials, this orally active agent 
was tested in patients with postherpetic neuralgia, painful 
diabetic neuropathy [79–82] and CIPN [78]. Although 
EMA401 showed antineuropathic properties in the post-
herpetic neuralgia and painful diabetic neuropathy patient 
populations, these trials were withdrawn or terminated due 
to the side effects observed [108–111].
A phase II clinical trial of EMA401 in patients suffer-
ing from CIPN was conducted as an open-label biomarker 
study designed to provide a proof of concept of the use of 
EMA401 in CIPN due to taxanes or platinum derivatives. 
In this trial, the primary endpoint was the change (i.e., a 
decrease of at least 30%) in mean spontaneous pain intensity 
score between baseline and the last week of 28 days of 
EMA401 dosing. A number of secondary endpoints were 
also evaluated, including changes in nerve characteristics 
in skin biopsies taken from the calf, change in evoked (light 
touch) mean pain intensity score from baseline over time, 
change in evoked (cold touch) mean pain intensity score 
over time and patient global impression of change [109]. It 
has to be noted that the results of this trial are inconclusive 
and difficult for interpretation because statistical analyses 
have not been specified as only one arm was reported [78].
Future outlook: data from preclinical studies
Although the mechanisms underlying CIPN are relatively 
well understood, the available results of clinical trials clearly 
indicate that the success rate for the introduction of novel 
drugs that are able to prevent CIPN is low [50], the progress 
in this area is slow and, at present, there is insufficient evi-
dence to recommend any specific agent for CIPN prevention. 
Hence, animal research is a strong scientific and practical 
demand, because it enables the discovery and development 
of novel interventions for this clinical entity. Since mecha-
nism-based therapies are urgently needed [112], novel tar-
gets are being explored to develop potential drug candidates. 
However, the drug development process is both time- and 
cost-consuming. Therefore, drug repurposing, i.e., the iden-
tification of new clinical applications for registered drugs, is 
also a valuable alternative approach to drug discovery and 
development research [113].
In this context, targeting sterile alpha and TIR motif-
containing protein 1 (SARM-1), an injury-inducible nicoti-
namide adenine dinucleotide glycohydrolase (NADase) that 
triggers axon loss, is an emerging strategy for the preven-
tion of CIPN-related axon degeneration (Fig. 2), and some 
SARM-1-targeting agents are currently in development. In 
addition to small-molecule inhibitors, a very potent, domi-
nant-negative version of SARM-1 was developed. It acts by 
blocking the activation of wild-type SARM-1, and this pro-
tects axons from damage. Gene therapy using AAV-medi-
ated delivery of this SARM-1 dominant-negative molecule 
provided long-lasting axonal protection [114]. In addition, 
SARM1-mediated NADH dehydrogenase subunit I (NAD1) 
destruction and loss is compensated by the development of 
NAD1 precursors, which have the potential ability to pro-
tect axons. These NAD1 precursors are natural products that 
have potential utility in CIPN prevention [114]. In addition 
to the direct influence on SARM-1, targeting the upstream 
pathways regulating SARM-1 to prevent CIPN is of interest. 
Efforts have been made to boost the function and increase 
the expression of nicotinamide nucleotide adenylyltrans-
ferase 2 (NMNAT2). Targeting the degradation of NMNAT2 
might also be an alternative for neuropathy [114–116].
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Ethoxyquin was recently identified as a neuroprotective 
compound showing potential benefits in toxic neuropathies. 
Its efficacy without compromising antitumor efficacy was 
demonstrated against paclitaxel-induced CIPN in  vivo. 
Ethoxyquin also prevented cisplatin-induced neurotoxicity 
in vitro. In vivo, chronic administration of ethoxyquin par-
tially attenuated cisplatin-induced abnormalities. The neu-
roprotective effect of ethoxyquin is thought to result from 
the inhibition of the chaperone activity of heat shock protein, 
Hsp90 [117, 118].
Bclw is a death-protecting member of the Bcl2 family of 
apoptosis-regulating proteins. The increased levels or activ-
ity of Bclw might also represent a novel therapeutic target 
for the prevention of CIPN (Fig. 2). Bclw was shown to 
play a role in paclitaxel-induced CIPN. Paclitaxel reduced 
axonal Bclw synthesis, altered intracellular calcium flux 
and activated calpain proteases. It also selectively impaired 
axonal trafficking of RNA granules and initiated inositol 
trisphosphate  (IP3)-receptor-dependent axon degeneration 
[119]. Thus, the modulation of Bclw levels [101], as well as 
the design of Bclw mimetics [119], might represent another 
novel therapeutic strategy for CIPN prevention.
Since oxidative stress in the nervous system is one of 
triggering factors for CIPN, and an impaired mitochon-
drial antioxidant response after paclitaxel, oxaliplatin and 
bortezomib is thought to underlie CIPN [120], novel mito-
chondria-targeting antioxidants have also been evaluated. 
In mice, SS-31 prevented symptoms of acute neuropathy 
caused by oxaliplatin [121].
In CIPN, for the protection of mitochondria, the inhi-
bition of nitro-oxidative stress with novel potential drugs 
might also include the use of the mitochondrial protect-
ant pifithrin-µ, which acts by inhibiting mitochondrial p53 
accumulation [122, 123], histone deacetylase 6 inhibitors 
[124], metformin [44, 74, 125], peroxynitrite decomposi-
tion catalysts [126], and antioxidants and anti-inflammatory 
cytokines, such as interleukin (IL) 10 [125, 127] (Fig. 2).
In addition, the targeting of inflammation and its markers 
in glial cells and peripheral immune system might contribute 
to CIPN prevention. Etanercept, a tumor necrosis factor-α 
(TNFα)-targeting antibody, decreased levels of IL-1α, IL-1β, 
IL-6, TNFα, interferon γ (INF-γ) and monocyte chemoat-
tractant protein-1 (MCP-1), (Fig. 2) and reduced painful 
symptoms caused by paclitaxel, showing a potential utility 
of etanercept as a CIPN-preventing drug [128].
The neuroprotective potential of niclosamide in CIPN 
induced by oxaliplatin was confirmed in mice, normal 
neuron-like cells and cancer cells. In neuron-like cells, 
niclosamide reduced the production of oxaliplatin-medi-
ated hydrogenium peroxide, thereby preventing cell death. 
In colon cancer cells, niclosamide enhanced oxaliplatin-
mediated cell death through increased hydrogenium perox-
ide production. In neuropathic mice, niclosamide prevented 
tactile hypoesthesia, thermal hyperalgesia and decreased 
neuronal hyperexcitability. Niclosamide prevented oxalipl-
atin-induced increased levels of IL-6 and TNFα (Fig. 2) and 
reduced oxidative stress. Taken together, niclosamide dis-
played antitumor and neuroprotective effects without reduc-
ing the antitumor efficacy of oxaliplatin [129].
As mentioned above, peripheral immune system cells 
such as macrophages and monocytes have been shown to be 
targets of CIPN mechanisms. In this context, another poten-
tial strategy to prevent CIPN is the targeting of chemokines 
and their receptors. For instance, blocking MCP-1 (CCR2) 
signaling might be an effective therapeutic strategy to pre-
vent or reverse CIPN caused by paclitaxel [130].
Chemokine receptor CXCR1/CXCR2 ligands also show 
some promising CIPN-preventing properties. Brandolini and 
colleagues investigated the effect of reparixin, an inhibitor 
of CXCR1/CXCR2, in the suppression of the development 
of paclitaxel-induced neuropathic pain in rats. Reparixin 
attenuated paclitaxel-induced mechanical and cold allodynia 
in rats. This study suggested that the inhibition of CXCR1/
CXCR2 combined with standard taxane therapy, in addi-
tion to potentiating the taxane antitumor activity, can reduce 
paclitaxel-induced neurotoxicity, thus giving some insight 
for the development of novel treatments [131]. Dual inhibi-
tors of CXCR1/CXCR2 were also tested in the oxaliplatin-
induced neuropathic pain model. One of such compounds, 
DF2726A, reduced pain behavior in oxaliplatin-treated rats. 
This study confirmed that IL-8 (CXCL8) and its receptors 
CXCR1/CXCR2 [132] are involved in the development of 
CIPN caused by oxaliplatin, and blocking the CXCL8 path-
way by DF2726A can significantly counteract neurotoxic 
effects resulting from oxaliplatin administration [133].
Novel therapies based on chemokine CX3CL1 (frac-
talkine) and its receptor expressed on monocytes, [134] have 
also emerged as potential options to alleviate CIPN symp-
toms [135]. It has been shown that gastrodin relieved vin-
cristine-induced CIPN in rats by inhibiting the activation of 
spinal microglia through CX3CL1 and its receptor, CX3CR1 
[136].
Using the oxaliplatin model of CIPN, it has also been 
demonstrated that the increased expression of C–C 
chemokine ligand 2 (CCL2) and its receptor, CCR2, in the 
dorsal root ganglia was lowered after intrathecal administra-
tion of anti-CCL2 antibodies, which prevented the devel-
opment of oxaliplatin-induced mechanical hypersensitivity 
[137].
In a mouse model of oxaliplatin-induced CIPN, it has also 
been demonstrated that thrombomodulin α, a recombinant 
human soluble thrombomodulin, prevented allodynia, most 
likely via a thrombin-dependent antineuropathic action. The 
oral anticoagulants warfarin, dabigatran and rivaroxaban 
suppressed this beneficial antineuropathic effect of throm-
bomodulin α [138].
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Matrix metalloproteinases (MMPs) are also a class of 
enzymes that have emerged as potential targets for CIPN-
preventing drugs. An increase in MMP2 and MMP9 and a 
decrease in metallopeptidase inhibitor 1 (TIMP1), a strong 
endogenous MMP9 inhibitor, were observed in a paclitaxel 
mouse model of CIPN.
Intrathecal injections of exogenous TIMP1 or a monoclo-
nal antibody targeting MMP9 (MMP9 mAb) significantly 
prevented and reversed paclitaxel-induced mechanical allo-
dynia in mice. This antibody significantly decreased oxida-
tive stress and levels of neuroinflammatory IL-6 and TNFα. 
MMP9 mAb prevented paclitaxel-induced intraepidermal 
nerve fiber loss. Hence, it was suggested that MMP9 mAb 
has therapeutic potential for the treatment of CIPN. Impor-
tantly, a humanized MMP9 antibody (andecaliximab) has 
reached advanced clinical trials for the treatment of colitis 
(ClinicalTrials.gov: NCT02405442) [139, 140] and alimen-
tary tract cancer (ClinicalTrials.gov: NCT01803282) [141, 
142]; hence, it may also be repurposed for CIPN [143].
Our unpublished studies, as well as research results from 
other laboratories, indicate that minocycline, a tetracycline 
antibiotic, a microglia inhibitor and a MMP9 blocker, alle-
viates the development and symptoms of CIPN caused by 
oxaliplatin, cisplatin, paclitaxel and bortezomib [144–148].
Animal models have also indicated that the targeting 
of receptors expressed within pain pathways might be an 
important pharmacological approach for CIPN-preventing 
drugs. In mice, the blockade of muscarinic receptors with 
the use of benztropine prevented both acute and chronic 
symptoms of peripheral neuropathy caused by oxaliplatin. 
In in vitro studies, benztropine also attenuated electrophysi-
ological alterations due to CIPN and prevented the decrease 
in neuronal density in the paws of mice that were injected 
with oxaliplatin. A lower tumor growth was observed in 
mice receiving benztropine when compared to untreated 
animals, and benztropine acted synergistically with oxali-
platin by increasing its anticancer effect. This activity was 
attributed to the influence of benztropine on ROS imbalance 
in tumor cells [149].
Nicotine is under investigation as another potential thera-
peutic strategy within the cholinergic system for both the 
prevention and the treatment of paclitaxel-induced CIPN. 
Available data suggest that the targeting of the nicotinic-ace-
tylcholine-receptor-mediated pathway may be a promising 
strategy for the prevention and treatment of CIPN-induced 
symptoms, in particular mechanical allodynia and intraepi-
dermal nerve fiber loss [150]. A primary concern is that nic-
otine may also stimulate tumor growth, and smoking history 
has been classified as a risk factor for CIPN. The research is 
focused on nicotinic receptor agonists as novel strategies for 
the prevention and treatment of CIPN [150, 151].
R-47, an α7 nAChR silent agonist, showed promising 
activity for the prevention and treatment of CIPN caused 
by paclitaxel. Its activity did not interfere with the antitu-
mor activity of paclitaxel. No tolerance developed following 
repeated administration of R-47, and R-47 lacked intrinsic 
rewarding effects. Additionally, R-47 did not influence the 
rewarding effects of nicotine in the conditioned place pref-
erence test in mice, and it did not enhance mecamylamine-
precipitated withdrawal [151].
Cebranopadol (a.k.a. GRT-6005) is a first-in-class potent 
analgesic compound with agonistic activity at nociceptin/
orphanin FQ and opioid receptors [152]. It has been recently 
developed in phase II clinical trials for the treatment of 
painful diabetic neuropathy or cancer pain. Subcutaneously 
administered cebranopadol reduced cold allodynia in oxali-
platin-treated mice, and this effect was observed both in the 
acute and the late phase of CIPN [153].
In rodent models, the administration of carvedilol, a 
β-adrenolytic drug with cardioprotective properties, reduced 
levels of nitrotyrosine and subsequently increased the 
expression of mitochondrial SOD in both sciatic nerves and 
dorsal root ganglia. Based on this mechanism of action, it 
was suggested that this drug might have the potential for pre-
venting an alteration in mitochondrial membrane potential 
in nerves and the loss of intraepidermal nerve fiber density. 
Several ongoing studies evaluating carvedilol for a variety of 
clinical conditions, but, at present, there is no clinical study 
for the prevention of CIPN [4].
A series of novel amide derivatives of 1,3-dimethyl-
2,6-dioxopurin-7-yl-alkylcarboxylic acids, analogs of a 
TRPA1 antagonist, i.e., HC-030031, were assessed in vitro 
and in  vivo. These compounds were identified as dual 
TRPA1 channel antagonists and phosphodiesterase 4B/7A 
inhibitors. They reduced tactile allodynia in oxaliplatin-
treated mice and showed TNFα-lowering properties; there-
fore, they are regarded as interesting drug candidates for 
CIPN [154].
Hyperpolarization-activated cyclic nucleotide-gated 
(HCN) channels are overexpressed in various inflamma-
tory and neuropathic pain states, and a novel HCN1 inhibi-
tor, MEL57A, has recently demonstrated antiallodynic and 
antihyperalgesic properties in oxaliplatin-treated rats. HCN1 
channels were proposed as a new drug target in CIPN, and 
HCN1-selective inhibitors might be a new class of medica-
tions for CIPN [155].
Many mechanisms underlying CIPN overlap and can 
reinforce each other. Thus, a combination drug therapy 
might also be an interesting and more efficacious (com-
pared to monotherapy) approach to CIPN prevention [120]. 
Although there are no clear algorithms for the clinical use 
of combined drugs in CIPN patients, data from preclini-
cal research indicate that certain drug combinations might 
effectively attenuate symptoms of CIPN [156]. In our 
recent study, a hyperadditive effect of combined subanalge-
sic doses of ambroxol and pregabalin on cold allodynia was 
520 K. Sałat 
1 3
demonstrated in oxaliplatin-treated mice. This effect was 
particularly strong when both drugs were given simultane-
ously or sequentially, i.e., 4 h apart. These results point out a 
synergistic reaction between  Nav and  Cav channel inhibitors 
in CIPN caused by oxaliplatin [156].
Mesenchymal stem cell (MSC) therapy is also an emerg-
ing attractive approach for CIPN. Evidence has demonstrated 
that MSCs reduce oxidative stress, neuroinflammation, 
and neuronal cell apoptosis and stimulate axon regenera-
tion after nerve damage. Hence, MSC-based therapies may 
provide a new therapeutic strategy for patients suffering 
from CIPN. Combined therapy using ‘traditional’ phar-
macological agents and MSCs might also be an interesting 
approach for CIPN prevention and treatment [157].
Several studies have also been conducted to assess 
whether targeting pathways associated with gut microbiota 
might be a way to overcome CIPN [158]. Probiotics show 
therapeutic effects in various diseases, such as travelers’ 
diarrhea or irritable bowel syndrome, and previous studies 
have also confirmed their protective role in various nocic-
eptive pain states [159–161], but, at present, little is known 
about their potential effect on CIPN.
Using F11 cells, the probiotic DSF was tested for its abil-
ity to attenuate paclitaxel-induced neuropathic pain. The 
results obtained suggested its potential use as an adjuvant 
agent for CIPN [162]. The following mechanisms explain 
a beneficial effect of probiotics through which they might 
inhibit CIPN: a reduction in proinflammatory cytokine 
levels, the regulation of the balance between anti-inflam-
matory and proinflammatory cytokines, the inhibition of 
neutrophil infiltration and increased intestinal permeability, 
augmented production of short-chain fatty acids, the inhibi-
tion of ammonia formation, changes in the expression levels 
of toll-like receptors: TLR2 and TLR4, the maintenance of 
mucosal integrity through mucin secretion and the activation 
of suppressive T-cell populations [158]. Here, it should be 
strongly emphasized that the research on the gut microbiome 
in CIPN is still at an exploratory stage, and potential thera-
peutic methods based on microbiota manipulation require 
further preclinical and clinical research. In particular, clini-
cal trials assessing the use of probiotics to prevent or treat 
CIPN are a strong medical demand [158].
The efficacy of complementary therapies in the pre-
vention and treatment of CIPN has also been a subject of 
research. Herbal medicinal therapies (e.g., Acorus calamus, 
Cannabis species, Matricaria chamomilla, Ginkgo biloba, 
Curcuma longa, Camellia sinensis) counteract phenom-
ena underlying CIPN, i.e., they reduce oxidative stress and 
attenuate inflammation in animals [163], but their utility for 
CIPN prevention requires further investigation to confirm 
their efficacy and safety [164–167].
In addition to novel pharmacological targets for the 
prevention and/or treatment of CIPN, nonpharmacologi-
cal approaches were also assessed. Interestingly, a grow-
ing body of literature suggests that exercise can prevent 
CIPN. In rodent models of CIPN, volitional wheel running 
reduced both the development and the maintenance of cold 
and mechanical allodynia. This finding was confirmed in 
patients assigned to the exercise group during chemotherapy 
who reported less severe thermal and sensory symptoms of 
CIPN than patients who received chemotherapy alone [94].
Preclinical data regarding potential future preventative 
therapies for CIPN are summarized in Table 3.
Conclusions
Although preclinical models reflecting CIPN have provided 
a deeper insight into mechanisms that initiate and maintain 
antitumor drug-induced neurotoxicity, this clinical entity 
currently cannot be prevented. New therapeutic approaches 
and drug targets should be assessed, and improved clini-
cal trials need to be designed to search for drugs for CIPN 
prevention. This research should address genotypic profiles 
of patients suffering from CIPN, and the knowledge regard-
ing genetic CIPN susceptibility needs to be incorporated 
into clinical trials. This research not only would contribute 
to recent advances in basic and translational research for 
CIPN prevention [168] but also would enable the predic-
tion of patients’ susceptibility to CIPN development prior 
to starting chemotherapy based on CIPN-inducing drugs. In 
addition, pharmacogenomics studies could be useful in the 
identification of mutations in genes influencing antitumor 
drug metabolism, and this could also be an important source 
of data for optimal dosing of these drugs in patients [101].
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